Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Daclizumab Induction in Kidney Transplant
NCT01172418Phase 4Completed
- Sponsor
- University of Miami
- Start
- Feb 2006
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab in kidney failure (ESRD) (2 arms), sponsored by University of Miami. Primary endpoint: Incidence of Acute Rejection at One Year Post-transplant at 1 year. Started Feb 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT01172418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172418.